FCP
EBS icon

Fidelis Capital Partners’s Emergent Biosolutions EBS Stock Holding History

Fidelis Capital Partners’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-24,017
Closed -$60.8K – 384
2024
Q1 		$60.8K Buy
+24,017
New +$54.1K 0.01% 363

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Fidelis Capital Partners's EBS Position: Q2 2024 in Review

Fidelis Capital Partners sold out of Emergent Biosolutions (EBS) in Q2 2024, closing a stake of 24,017 shares — an estimated $60.8K sold.

Fidelis Capital Partners first reported a position in EBS in Q1 2024 and held it in 1 quarter. The position peaked at $60.8K in Q1 2024. 141 funds tracked by Wall St. Rank hold EBS as of Q2 2024.

  • Fidelis Capital Partners reported no remaining Emergent Biosolutions position as of Q2 2024 after selling out during the quarter.
  • Fidelis Capital Partners sold 24,017 Emergent Biosolutions shares in Q2 2024, an estimated $60.8K.
  • Fidelis Capital Partners first reported a position in Emergent Biosolutions in Q1 2024 and held it in 1 quarter.
  • Fidelis Capital Partners's Emergent Biosolutions position peaked at $60.8K in Q1 2024.
  • 141 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2024.

Based on Fidelis Capital Partners's 13F filing for Q2 2024, filed 13 Aug 2024.